Skip to main content
Top
Published in: BMC Primary Care 1/2020

Open Access 01-12-2020 | Dyslipidemia | Research article

Lifetime risk assessment in cholesterol management among hypertensive patients: observational cross-sectional study based on electronic health record data

Authors: Aapo Tahkola, Päivi Korhonen, Hannu Kautiainen, Teemu Niiranen, Pekka Mäntyselkä

Published in: BMC Primary Care | Issue 1/2020

Login to get access

Abstract

Background

In hypertensive patients, reducing plasma low-density lipoprotein cholesterol level (LDL-C) is one of the main interventions for preventing chronic cardiovascular diseases (CVD). However, LDL-C control remains generally insufficient, also in patients with hypertension. We analyzed Electronic Health Record (EHR) data of 7117 hypertensive patients to find the most potential age and sex subgroups in greatest need for improvement in real life dyslipidemia treatment. Taking into account the current discussion on lifetime CVD risk, we focused on the age dependence in LDL-C control.

Methods

In this observational cross-sectional study, based on routine electronic health record (EHR) data, we investigated LDL-C control of hypertensive, non-diabetic patients without renal dysfunction or CVD, aged 30 years or more in Finnish primary care setting.

Results

More than half (54% of women and 53% of men) of untreated patients did not meet the LDL-C target of < 3 mmol/l and one third (35% of women and 33% of men) of patients did not reach the target even with the lipid-lowering medication (LLM). Furthermore, higher age was strongly associated with better LDL-C control (p < 0.001) and lower LDL-C level (p < 0.001) in individuals with and without LLM. Higher age was also strongly associated with LLM prescription (p < 0.001). In total, about half of the patients were on LLM (53% of women and 51% of men).

Conclusions

Our findings indicate that dyslipidemia treatment among Finnish primary care hypertensive patients is generally insufficient, particularly in younger age groups who might benefit the most from CVD risk reduction over time. Clinicians should probably rely more on the lifetime risk of CVD, especially when treating working age hypertensive patients.
Literature
1.
go back to reference Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group. Arch Intern Med. 1992;152(7):1490–500.CrossRef Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group. Arch Intern Med. 1992;152(7):1490–500.CrossRef
2.
go back to reference Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.CrossRef Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.CrossRef
3.
go back to reference Authors/Task Force Members, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias: the task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.CrossRef Authors/Task Force Members, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias: the task force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.CrossRef
4.
go back to reference Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther. 2007;29(5):778–94.CrossRef Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther. 2007;29(5):778–94.CrossRef
5.
go back to reference Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC, Sanghavi DM, Brown NC, Korenovska L, Huffman MD. Drugs for primary prevention of Atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. 2016;1(3):341–9.CrossRef Karmali KN, Lloyd-Jones DM, Berendsen MA, Goff DC, Sanghavi DM, Brown NC, Korenovska L, Huffman MD. Drugs for primary prevention of Atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. 2016;1(3):341–9.CrossRef
6.
go back to reference Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
7.
go back to reference Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRef Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRef
8.
go back to reference Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332(7550):1115–24.CrossRef Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332(7550):1115–24.CrossRef
9.
go back to reference Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC scientific document group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.CrossRef Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC scientific document group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.CrossRef
10.
go back to reference Borodulin K, Vartiainen E, Peltonen M, Jousilahti P, Juolevi A, Laatikainen T, Mannisto S, Salomaa V, Sundvall J, Puska P. Forty-year trends in cardiovascular risk factors in Finland. Eur J Pub Health. 2015;25(3):539–46.CrossRef Borodulin K, Vartiainen E, Peltonen M, Jousilahti P, Juolevi A, Laatikainen T, Mannisto S, Salomaa V, Sundvall J, Puska P. Forty-year trends in cardiovascular risk factors in Finland. Eur J Pub Health. 2015;25(3):539–46.CrossRef
11.
go back to reference Kotseva K, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Abreu A, Aguiar C, Conde AC, Davletov K, Dilic M, Dolzhenko M, Gaita D, Georgiev B, Gotcheva N, Lalic N, Laucevicius A, Lovic D, Mancas S, Milicic D, Oganov R, Pajak A, Pogosova N, Reiner Z, Vulic D, Wood D, On Behalf Of The Euroaspire, Investigators. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol. 2016;23(18):2007–18.CrossRef Kotseva K, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Abreu A, Aguiar C, Conde AC, Davletov K, Dilic M, Dolzhenko M, Gaita D, Georgiev B, Gotcheva N, Lalic N, Laucevicius A, Lovic D, Mancas S, Milicic D, Oganov R, Pajak A, Pogosova N, Reiner Z, Vulic D, Wood D, On Behalf Of The Euroaspire, Investigators. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol. 2016;23(18):2007–18.CrossRef
12.
go back to reference Ho LT, Yin WH, Chuang SY, Tseng WK, Wu YW, Hsieh IC, Lin TH, Li YH, Huang LC, Wang KY, Ueng KC, Fang CC, Pan WH, Yeh HI, Wu CC, Chen JW, Taiwanese secondary prevention for patients with AtheRosCLErotic disease (T-SPARCLE) registry investigators. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan. PLoS One. 2015;10(3):e0116513.CrossRef Ho LT, Yin WH, Chuang SY, Tseng WK, Wu YW, Hsieh IC, Lin TH, Li YH, Huang LC, Wang KY, Ueng KC, Fang CC, Pan WH, Yeh HI, Wu CC, Chen JW, Taiwanese secondary prevention for patients with AtheRosCLErotic disease (T-SPARCLE) registry investigators. Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan. PLoS One. 2015;10(3):e0116513.CrossRef
13.
go back to reference Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):e001800.CrossRef Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):e001800.CrossRef
14.
go back to reference Russo G, Pintaudi B, Giorda C, Lucisano G, Nicolucci A, Cristofaro MR, Suraci C, Mulas MF, Napoli A, Rossi MC, Manicardi V. Age- and gender-related differences in LDL-cholesterol Management in Outpatients with type 2 diabetes mellitus. Int J Endocrinol. 2015;2015:957105.PubMedPubMedCentral Russo G, Pintaudi B, Giorda C, Lucisano G, Nicolucci A, Cristofaro MR, Suraci C, Mulas MF, Napoli A, Rossi MC, Manicardi V. Age- and gender-related differences in LDL-cholesterol Management in Outpatients with type 2 diabetes mellitus. Int J Endocrinol. 2015;2015:957105.PubMedPubMedCentral
15.
go back to reference Ambrose JA, Najafi A. Strategies for the prevention of coronary artery disease complications: can we do better? Am J Med. 2018;131(9):1003–9.CrossRef Ambrose JA, Najafi A. Strategies for the prevention of coronary artery disease complications: can we do better? Am J Med. 2018;131(9):1003–9.CrossRef
16.
go back to reference Domanski MJ, Fuster V, Diaz-Mitoma F, Grundy S, Lloyd-Jones D, Mamdani M, Roberts R, Thorpe K, Hall J, Udell JA, Farkouh ME. Next steps in primary prevention of coronary heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66(16):1828–36.CrossRef Domanski MJ, Fuster V, Diaz-Mitoma F, Grundy S, Lloyd-Jones D, Mamdani M, Roberts R, Thorpe K, Hall J, Udell JA, Farkouh ME. Next steps in primary prevention of coronary heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66(16):1828–36.CrossRef
17.
go back to reference Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624.CrossRef Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624.CrossRef
18.
go back to reference Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321–9.CrossRef Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321–9.CrossRef
19.
go back to reference Niiranen TJ, McCabe EL, Larson MG, Henglin M, Lakdawala NK, Vasan RS, Cheng S. Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham heart study. BMJ. 2017;357:j1949.CrossRef Niiranen TJ, McCabe EL, Larson MG, Henglin M, Lakdawala NK, Vasan RS, Cheng S. Heritability and risks associated with early onset hypertension: multigenerational, prospective analysis in the Framingham heart study. BMJ. 2017;357:j1949.CrossRef
20.
go back to reference The medical research decree of 1999, Pub. L. No. 986 of 1999. Finnish. The medical research decree of 1999, Pub. L. No. 986 of 1999. Finnish.
21.
go back to reference Anonymous ICD-10. International Statistical Classification of Diseases and Related Health Problems, 10th revision. 2011. Anonymous ICD-10. International Statistical Classification of Diseases and Related Health Problems, 10th revision. 2011.
22.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRef Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRef
23.
go back to reference Anonymous. Update on current care guideline: dyslipidaemias. Duodecim. 2013;129(11):1198–9. Anonymous. Update on current care guideline: dyslipidaemias. Duodecim. 2013;129(11):1198–9.
24.
go back to reference Sabate E. Adherence to long-term therapies: Evidence for action; 2003. Sabate E. Adherence to long-term therapies: Evidence for action; 2003.
25.
go back to reference Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, Pettitt D, Kerr EA, Selby JV. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med. 2006;144(7):475–84.CrossRef Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, Pettitt D, Kerr EA, Selby JV. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med. 2006;144(7):475–84.CrossRef
26.
go back to reference Zamora A, Fernandez de Bobadilla F, Carrion C, Vazquez G, Paluzie G, Elosua R, Vilaseca M, Martin-Urda A, Rivera A, Plana N, Masana L, VALIDA study group, network of lipid units of Catalonia (XULA). Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). Atherosclerosis. 2013;231(2):401–4.CrossRef Zamora A, Fernandez de Bobadilla F, Carrion C, Vazquez G, Paluzie G, Elosua R, Vilaseca M, Martin-Urda A, Rivera A, Plana N, Masana L, VALIDA study group, network of lipid units of Catalonia (XULA). Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). Atherosclerosis. 2013;231(2):401–4.CrossRef
27.
go back to reference Alagoz E, Chih MY, Hitchcock M, Brown R, Quanbeck A. The use of external change agents to promote quality improvement and organizational change in healthcare organizations: a systematic review. BMC Health Serv Res. 2018;18(1):42–018.CrossRef Alagoz E, Chih MY, Hitchcock M, Brown R, Quanbeck A. The use of external change agents to promote quality improvement and organizational change in healthcare organizations: a systematic review. BMC Health Serv Res. 2018;18(1):42–018.CrossRef
28.
go back to reference Kokko S, Virta L, Vehko T. The roles and relative contributions of municipal health centres and alternative service providers in the management of type 2 diabetes and hypertension in Finland. Finnish Med J. 2015;70(44):2945–9. Kokko S, Virta L, Vehko T. The roles and relative contributions of municipal health centres and alternative service providers in the management of type 2 diabetes and hypertension in Finland. Finnish Med J. 2015;70(44):2945–9.
29.
go back to reference Abbott RD, Garrison RJ, Wilson PW, Epstein FH, Castelli WP, Feinleib M, LaRue C, Joint distribution of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis. 1983;3(3):260–72.CrossRef Abbott RD, Garrison RJ, Wilson PW, Epstein FH, Castelli WP, Feinleib M, LaRue C, Joint distribution of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis. 1983;3(3):260–72.CrossRef
30.
go back to reference Morgan AE, Mooney KM, Wilkinson SJ, Pickles NA, Mc Auley MT. Cholesterol metabolism: a review of how ageing disrupts the biological mechanisms responsible for its regulation. Ageing Res Rev. 2016;27:108–24.CrossRef Morgan AE, Mooney KM, Wilkinson SJ, Pickles NA, Mc Auley MT. Cholesterol metabolism: a review of how ageing disrupts the biological mechanisms responsible for its regulation. Ageing Res Rev. 2016;27:108–24.CrossRef
31.
go back to reference Halava H, Huupponen R, Pentti J, Kivimaki M, Vahtera J. Predictors of first-year statin medication discontinuation: a cohort study. J Clin Lipidol. 2016;10(4):987–95.CrossRef Halava H, Huupponen R, Pentti J, Kivimaki M, Vahtera J. Predictors of first-year statin medication discontinuation: a cohort study. J Clin Lipidol. 2016;10(4):987–95.CrossRef
32.
go back to reference Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med. 1987;82(1B):54–60.CrossRef Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med. 1987;82(1B):54–60.CrossRef
33.
go back to reference Siven SS, Niiranen TJ, Aromaa A, Koskinen S, Jula AM. Social, lifestyle and demographic inequalities in hypertension care. Scand J Public Health. 2015;43(3):246–53.CrossRef Siven SS, Niiranen TJ, Aromaa A, Koskinen S, Jula AM. Social, lifestyle and demographic inequalities in hypertension care. Scand J Public Health. 2015;43(3):246–53.CrossRef
34.
go back to reference Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.CrossRef Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.CrossRef
Metadata
Title
Lifetime risk assessment in cholesterol management among hypertensive patients: observational cross-sectional study based on electronic health record data
Authors
Aapo Tahkola
Päivi Korhonen
Hannu Kautiainen
Teemu Niiranen
Pekka Mäntyselkä
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2020
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/s12875-020-01138-5

Other articles of this Issue 1/2020

BMC Primary Care 1/2020 Go to the issue